The big European Society of Cardiology world congress will be held in Barcelona next month.
Larry Husten of Cardiobrief.org shared an invitation he received from a PR company, which read, in part:
“…for an internal event organized by Sanofi Regeneron (PCSK9) on August 30 in Barcelona, we are looking for a moderator for the whole day to animate the plenary session of the meeting.
This moderator should be able to speak in front of 250 people, to animate the different roundtables organized during the day between KOL, patients and Sanofi Regeneron teams, and to “interview” the different speakers.Based on your experience and expertise, we are contacting you to know if you can be interested by this activity and if you have already managed this kind of event in the past?
Please note that a rehearsal is planned in Paris on August 20 (all day) and a rehearsal on site in Barcelona on August 29, and the attendance of the master of ceremony would be needed.”
Hmmm. A trip to Paris and to Barcelona…..
Husten won’t take them up on the offer.
He’s written about the PCSK9 drugs on his site. It’s a relatively new class of cholesterol-lowering drugs. The last thing I can see that he wrote about them was, “FDA Sprinkles Some Rain On the PCSK9 Inhibitor Parade.” Excerpt:
Last month Regeneron disclosed that it had been “advised by the FDA that it has become aware of neurocognitive adverse events in the PCSK9 inhibitor class. The FDA requested that Regeneron and its partner, Sanofi, “make an assessment of potential neurocognitive adverse events across the global development program” of their PCSK9 inhibitor, alirocumab.
Husten predicts that “the PR initiative on the PCSK9s is likely to be about as big as it gets these days.”
It’d be a nice coup for a PR company to lure a journalist who covers cardiology news fulltime to be a moderator/MC for a session about its client’s drug.
But Husten, we have a problem, just as you did with that arrangement, and we’re pleased to see you won’t bite.
——————
Follow us on Twitter:
https://twitter.com/garyschwitzer
https://twitter.com/healthnewsrevu
Opinions on other issues in news, journals, PR, advertising, marketing
A week like this should teach you how/what to ignore: #COVID19 news & PR about studies in monkeys & mice...about studies of dishonesty & BMI…and about rating attractiveness of women with endometriosis!!! https://www.healthnewsreview.org/2020/08/crazy-week-of-pr-news-on-studies-should-teach-us-how-what-to-ignore/
“to project certainty where it simply does not exist is communication malpractice at a time like this and with a public health issue like this.” @garyschwitzer on @ContentScience https://review.content-science.com/covering-covid-19-vaccine-news-part-two-from-the-publisher-of-health-news-review/
In case you weren't aware: Prestigious journalism organizations and outlets take money from pharma, @garyschwitzer https://www.healthnewsreview.org/2020/08/drug-company-influence-on-journalism/#.XyrYGZeNvXA.twitter @HealthNewsRevu
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Comments are closed.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like